Insulin Therapy Guidelines
Introduction to Long-Acting Insulins
- Long-acting insulins, such as Tresiba (insulin degludec) and Lantus (insulin glargine), provide relatively constant insulin levels over approximately 24 hours, with their primary action being to restrain hepatic glucose production and limit hyperglycemia between meals and overnight, as supported by the American Diabetes Association and Endocrine Society guidelines 1, 2
- The American Diabetes Association and Endocrine Society guidelines support once-daily dosing of Tresiba, although clinical judgment and patient response may guide the decision for twice-daily dosing in some cases, particularly for patients with type 1 diabetes 1, 2
Dosage Adjustments and Considerations
- Avoid overbasalization with insulin therapy, as doses exceeding 0.5 units/kg/day can lead to hypoglycemia, according to the American Diabetes Association guidelines 1, 2
- Small incremental changes (1-2 units or 5-10% of current dose) are recommended when adjusting long-acting insulin dosages, such as Tresiba and Lantus, to minimize the risk of hypoglycemia, as suggested by the American Diabetes Association and American College of Endocrinology 1, 3
- Increasing the morning dose of long-acting insulins, such as Lantus, can increase the risk of nocturnal hypoglycemia, particularly if the dose exceeds 0.5 units/kg/day, as reported by the Endocrine Society 1
Special Considerations
- For patients with type 1 diabetes, long-acting insulins, such as insulin glargine, may require twice-daily dosing in some cases, though clinical judgment and patient response guide this decision, as noted by the American Diabetes Association and Endocrine Society 1, 2
- If 24-hour coverage isn't achieved with once-daily dosing, splitting the total daily dose may be considered, based on clinical guidelines and patient-specific factors, as recommended by the Endocrine Society 1, 2
- Patients should monitor overnight patterns by checking blood glucose at bedtime, 3 AM, and upon waking for several nights, and consider reducing the dose if any hypoglycemia occurs, as suggested by the American Association of Clinical Endocrinologists 4
- The timing of long-acting insulin administration, such as Lantus, affects its overnight impact, and morning administration may result in a steady basal insulin level throughout the day and night, according to the American Association of Clinical Endocrinologists 2
Monitoring and Safety
- To ensure safety when increasing morning long-acting insulin, monitor overnight blood glucose patterns before making dose adjustments, and check glucose levels at bedtime, overnight (3 AM if possible), and upon waking, as suggested by the American Association of Clinical Endocrinologists 4
- If overnight control is problematic with morning long-acting insulin, consider switching to bedtime administration or splitting the total daily dose if 24-hour coverage isn't achieved with once-daily dosing, as recommended by the Endocrine Society 2